YolTech Therapeutics reports positive clinical data for the first in vivo gene-editing therapy in primary hyperoxaluria type 1, Precision BioSciences...

Caribou Biosciences expands its clinical programme for CB-010 with FDA nod to initiate clinical trial in lupus, Verve Therapeutics pauses ongoing...

As 2023 draws to a close, we look back on some of the major clinical highlights from the year gone by.

Verve Therapeutics has announced the first human proof-of-concept data demonstrating durable reductions in cholesterol for its in vivo base-editing...

In this clinical trial roundup, we present an overview of the ongoing clinical trials involving base-editing therapeutic candidates. This article...

Verve Therapeutics announced yesterday that its most advanced base-editing candidate VERVE-101 has been awarded the Innovation Passport for the...

Verve Therapeutics recently announced the first human dosing with VERVE-101, an investigational base-editing therapy that is designed to treat...

Verve Therapeutics announced last week that its clinical trial application for VERVE-101 in heterozygous familial hypercholesterolemia had been...